Article

A statistical immune correlates of protection model for predicting efficacy from neutralizing antibody titers to establish immunobridging of monoclonal antibodies for prevention of COVID-19

2025-07-24

Abstract excerpt

<h4>Background</h4> Neutralizing antibody titers are recognized as an acceptable surrogate efficacy endpoint for immunobridging next-generation monoclonal antibodies (mAbs) to those with demonstrated clinical efficacy for the prevention of COVID-19. However, titers measured at early time points after dosing overestimate the titer levels required for clinical protection, but long-term efficacy data is limited due...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 92593d21-97c1-50e7-9ad1-bfc3aeb12133
DOI: 10.1101/2025.07.24.25332145

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

A statistical immune correlates of protection model for predicting efficacy from neutralizing antibody titers to establish immunobridging of monoclonal antibodies for prevention of COVID-19DOI 10.1101/2025.07.24.25332145Read

Immunobridging Analysis of Pemivibart for the Treatment of COVID-19 – A Therapeutic Gap for the Immune Compromised RemainsSemantic proximity Read

Predicting immune protection against outcomes of infectious disease from population-level effectiveness data with application to COVID-19Semantic proximity Read

A modeling-based approach to optimize COVID-19 vaccine dosing schedules for improved protectionSemantic proximity Read

Determinants of passive antibody efficacy in SARS-CoV-2 infectionSemantic proximity Read

Quantifying the role of naturally- and vaccine-derived neutralizing antibodies as a correlate of protection against COVID-19 variantsSemantic proximity Read

Evidence for antibody as a protective correlate for COVID-19 vaccinesSemantic proximity Read

Immune Compromising Conditions Impair SARS-CoV-2 Vaccine Humoral Immunogenicity Despite Multiple Booster DosesSemantic proximity Read

Mechanistic model for booster doses effectiveness in healthy, cancer and immunosuppressed patients infected with SARS-CoV-2Semantic proximity Read

SARS-CoV-2 mechanistic correlates of protection: insight from modelling response to vaccinesSemantic proximity Read

Predicting COVID-19 Vaccine Efficacy from Neutralizing Antibody LevelsSemantic proximity Read

Durability of protection post-primary COVID-19 vaccination in the US: matched case-control studySemantic proximity Read

Safety and Efficacy of Pemivibart, a Long-Acting Monoclonal Antibody, for Prevention of Symptomatic COVID-19: Interim Results From the CANOPY Clinical TrialSemantic proximity Read